Technical articles
Key Judgments in Medical Hydrogel R&D: From Polymer Source and Crosslinking Strategy to Sterilization Planning, Scale-Up Feasibility, and Quality Control
Key Judgments in Medical Hydrogel R&D: From Polymer Source and Crosslinking Strategy to Sterilization Planning, Scale-Up Feasibility, and Quality Control
Introduction
Medical hydrogels have evolved from high-water-content materials that entered clinical use relatively early into an important class of materials spanning external dressings, local delivery, tissue repair, cell carriers, and various implantation scenarios. A 2024 clinical update review showed that hydrogels entering clinical research and practical use include not only injectable systems, but also non-injectable products such as topical and implantable hydrogels. This means that medical hydrogel R&D cannot be understood solely in terms of a single route of administration or a single product format, but instead requires simultaneous consideration of material source, crosslinking strategy, cargo compatibility, sterilization planning, as well as subsequent scale-up and quality control.
Medical hydrogel R&D involves several fundamental questions: what type of medical hydrogel is ultimately intended, whether the polymer source is appropriate, which gelation route should be used, which key data should be prioritized after gel formation, at what stage sterilization should be incorporated into the development process, and whether the system can later be scaled up consistently and incorporated into quality control. These questions directly affect material selection, network design, experimental evaluation, and subsequent development planning. This article is organized around these key issues.
1. First define the final use format: different types of medical hydrogels do not share the same R&D starting point
The final use format directly determines the R&D starting point for a medical hydrogel. External dressings place greater emphasis on fluid absorption, moisture retention, adhesion, and local irritation during replacement. Local injectable systems place greater emphasis on precursor fluid flow behavior, needle passability, in situ gelation rate, and residence time. Tissue repair scaffolds place greater emphasis on mechanical support, pore structure, and cell infiltration. Drug delivery systems place greater emphasis on loading mode, diffusion behavior, and release profile. Cell-related systems must additionally consider gelation conditions, cell viability, and mass transport.
Residence time and cargo type further narrow the range of suitable materials. Short-term covering materials place more weight on initial gel formation, local conformity, and short-term stability, whereas long-acting residence materials place more weight on network retention, degradation rate, and long-term compatibility. If the system contains small-molecule drugs, proteins, nucleic acids, or cells, the precursor solution temperature, pH, osmotic pressure, ionic environment, free-radical exposure, and byproducts must all be incorporated into the design early. Recent reviews discussing both cell therapy and non-cell therapy hydrogels likewise place these factors ahead of material selection and network design.
The table below summarizes the issues that should be prioritized early for common use formats, so that “what type of system is being developed” can be matched with “which questions should be examined first.”
1.1 | Early concerns and downstream evaluation priorities for medical hydrogels under different use formats
Use format | What should be confirmed first at the early stage | What still needs attention later | Common experimental bias |
External dressings | Fluid absorption, moisture retention, adhesion, initial mechanical stability | Performance after sterilization, packaging compatibility, local irritation during replacement | Focusing only on water content and initial film formation while overlooking changes after sterilization and storage |
Injectable local systems | Precursor rheology, needle passability, in situ gelation time | In vivo residence, degradation profile, sterilization planning | Focusing only on injectability while overlooking structural stability after gelation |
Drug-loaded hydrogels | Loading mode, diffusion behavior, initial release characteristics | Interplay between degradation and release, preservation of drug activity | Looking only at early release results while overlooking later release drift |
Cell-related systems | Whether gelation conditions are mild, cell viability | Mass transport, phenotype maintenance, sterile precursor solution and culture stability | Evaluating material properties first and only later adding cell compatibility assessment |
Tissue repair scaffolds | Mechanical matching, pore structure, shape retention | Tissue integration, long-term degradation, feasibility of scale-up manufacturing | Looking only at support strength while overlooking cell infiltration and later-stage degradation |
2. Judging polymer source: first distinguish the strengths and limitations of the material itself
The material sources of medical hydrogels can broadly be divided into natural polymers, synthetic polymers, and modified or composite systems. Different material sources lead to different priorities later in gelation route, mechanical performance, biological performance, and quality control.
2.1 Natural polymers: first examine biocompatibility and suitability for the biological environment
Natural polymers such as hyaluronic acid, alginate, collagen, gelatin, and chitosan are often prioritized for systems requiring good biocompatibility or adaptation to the tissue environment. These materials are widely used in wound repair, tissue repair, and cell-related studies because they more readily provide a basic environment closer to biological conditions.
With such materials, attention should be paid to raw material source, molecular weight distribution, residual impurities, and batch-to-batch variation. These factors directly affect rheology, gelation behavior, and result consistency. A material being suitable for biological applications does not mean subsequent experiments will necessarily be stable. Variability in the raw material is often what appears first.
2.2 Synthetic polymers: first examine structural design and result consistency
Polyethylene glycol, polyvinyl alcohol, polyvinylpyrrolidone, and various polymethacrylates are suitable for systems requiring precise control over structure, network properties, and mechanical performance. These materials are more advantageous in injectable systems, controlled-release systems, and studies requiring high reproducibility in manufacturing, because molecular structure, crosslinking density, and batch consistency are usually easier to control.
These materials require attention because their intrinsic biological signaling is relatively weak. If the system involves cell adhesion, tissue integration, or regulation of biological activity, it is often necessary to further introduce degradable linkages, adhesive groups, or other functional moieties. The material itself may be highly controllable, but its biological function often needs to be supplemented afterward.
2.3 Modified or composite systems: first examine whether multiple performance requirements can be balanced simultaneously
When a project requires both good biocompatibility and relatively stable network structure, higher mechanical strength, or clearer batch control, modified or composite systems are often more suitable for further development. Common approaches include chemical modification of natural polymers or combining natural and synthetic materials to simultaneously balance biological performance and engineering performance.
These systems require attention because formulations and processes become more complex. Once the number of material components increases, process control, quality evaluation, and interpretation of results all become more difficult. The strengths and weaknesses of a single material are easier to judge, whereas composite systems require clearer assignment of the role of each component within the network.
2.4 Key material selection considerations for different material types
Material type | Situations to prioritize | Issues requiring attention | Typical experimental tasks |
Natural polymers | Systems requiring good biocompatibility, adaptation to the cellular environment, or a basis for tissue repair | Effects of raw material variability, residual impurities, and batch differences on gelation and reproducibility, and the fact that some materials still require functionalization to better support cell adhesion or tissue integration | Wound repair, cell encapsulation, tissue repair |
Synthetic polymers | Systems requiring precise control of structure, mechanics, and network parameters, or high consistency of results | Intrinsically weak biological signaling, often requiring further functionalization | Injectable systems, controlled-release systems, reproducible manufacturing studies |
Modified or composite systems | Systems that need to simultaneously balance biological performance, mechanical strength, processability, and consistency | More complex formulations, with increased difficulty in process control and quality evaluation | Composite hydrogel systems that need to balance multiple properties |
3. Judging the crosslinking strategy: first examine how the network forms, then whether it can remain stable after gelation
The crosslinking strategy directly affects gelation conditions, network stability, and subsequent evaluation priorities. The same polymer can show different gelation environments, mechanical performance, and compatibility with cells or drugs when different crosslinking strategies are used. Crosslinking strategy is therefore one of the key judgments in medical hydrogel design.
3.1 Physical crosslinking: first examine whether the gelation conditions are mild
Physical crosslinking usually relies on ionic interactions, hydrogen bonding, hydrophobic association, temperature response, freeze-thaw treatment, or molecular self-assembly to form a network. A characteristic of this type of method is that gelation conditions are relatively mild and involve fewer additional reactive components, so it is common in systems containing cells, proteins, and some sensitive drugs. It should be noted that such networks are more sensitive to environmental conditions. Ionic strength, temperature, shear, and exchange with body fluids may all alter the gel structure.
3.2 Chemical crosslinking: first examine network stability and residual-related indicators
Chemical crosslinking forms a network through covalent bonds. Common routes include free-radical polymerization, photocrosslinking, click reactions, Michael addition, and various condensation reactions. These methods readily yield relatively stable mechanical performance and structural retention, and are therefore common in systems requiring stronger support, longer residence, or more stable release behavior. It should be noted that residual crosslinkers, initiators, and byproducts may affect local tolerance as well as compatibility with cells or drugs.
3.3 Dynamic reversible networks and multiple networks: first examine recoverability, viscoelastic behavior, and mechanical task
Dynamic reversible networks are commonly used in systems that need to combine injectability, self-healing, adhesion, stress recovery, or complex viscoelastic behavior. Multiple networks, by contrast, are more commonly used when further improvement in strength, toughness, and structural retention is needed. Recent reviews on dynamic hydrogels emphasize that the advantage of dynamic networks lies in their ability to simultaneously regulate flowability, recovery capability, and mechanical response, and they have therefore continued to attract attention in injectable, in situ gelling, and biomanufacturing-related studies. It should be noted that once the network becomes more complex, structural interpretation and condition optimization also become more difficult.
3.4 Summary table of key selection considerations for different crosslinking strategies
Crosslinking strategy | Situations to prioritize | Issues requiring attention | What should be confirmed first experimentally |
Physical crosslinking | Systems requiring mild gelation conditions, or systems containing cells, proteins, or sensitive drugs | The network is more sensitive to temperature, ionic strength, and shear | Whether the network becomes unstable under physiological conditions, and whether long-term morphology can be maintained |
Chemical crosslinking | Systems requiring a relatively stable network, long-term maintenance of structural integrity, or clear mechanical support | Effects of residual crosslinkers, initiators, and byproducts on compatibility | Post-crosslinking residues, mechanical stability, compatibility with cells or drugs |
Dynamic reversible networks or multiple networks | Systems requiring injection, spreading, gap filling, self-healing, or stress recovery | Greater network complexity increases the difficulty of condition optimization and result interpretation | Reversible bond exchange rate, recovery capability, and changes in viscoelasticity |
4. How to interpret key data: what different indicators each answer
After the system has been prepared, which data should be prioritized, and what does each of them indicate? Gelation time, rheology and mechanics, swelling and mass transport, degradation and release, and interfacial performance each answer questions at different levels and should be interpreted in conjunction with the specific use format.
Gelation time mainly indicates whether the operation proceeds smoothly. Rheology and mechanics mainly indicate whether the material can withstand deformation and load during use. Swelling, pore structure, and mass transport mainly indicate whether the system can maintain the required exchange of substances. Degradation and release mainly indicate whether the duration of function matches the residence time. Interfacial adhesion and local tolerance mainly indicate whether the material can remain stable in use after contacting tissue. These questions need to be separated before the data can have real interpretive value.
4.1 Main interpretation points corresponding to key indicators
Indicator | Main interpretation point | Systems that usually require particular attention | What abnormal readings may suggest |
Gelation time | Whether the operation proceeds smoothly and whether the system can stabilize promptly after placement | Injectable systems, printable systems | If too fast, clogging or operational difficulty may occur; if too slow, positioning may become unstable |
Precursor rheology and shear recovery | Whether the system can be injected, spread, or printed smoothly, and whether it can recover after shear | Injectable systems, dynamic network systems | Insufficient flowability or slow recovery will affect subsequent shaping and retention |
Storage modulus and compressive/tensile properties | Whether the system can meet the mechanical requirements of the target site | Supportive, filling, and tissue repair systems | Insufficient structural retention, or stiffness mismatch with the tissue environment |
Swelling, pore structure, and mass transport | Whether nutrients, drugs, proteins, and metabolites can be exchanged effectively | Delivery systems, cell-related systems | Unstable release curves, or difficulty in maintaining the cellular microenvironment |
Degradation and release | Whether residence time matches the duration of function | Long-acting residence systems, drug-loaded systems | Premature loss of function, or increased burden from long-term residual presence |
Interfacial adhesion and local tolerance | Whether stable adhesion and local tolerance can be maintained | Wound repair, tissue adhesion, local delivery systems | Increased local irritation, or unstable adhesion performance |
5. Sterilization planning must be brought forward: criteria for choosing terminal sterilization or aseptic preparation
5.1 Sterilization planning cannot be left until the late stage of development
For medical hydrogels, the sterilization route not only determines whether sterility requirements can be met, but also affects material structure, gelation behavior, mechanical performance, and cargo activity. Heat, irradiation, and gas treatment do not affect all systems in the same way. Therefore, the sterilization route should be determined as early as possible in combination with the material itself, cargo type, and process conditions.
5.2 Terminal sterilization and aseptic preparation are not the same type of processing route
Terminal sterilization is applied at the finished-product stage or near-finished-product stage. Aseptic preparation, by contrast, moves sterility control forward into the preparation and forming process when the system cannot tolerate terminal sterilization. If the material itself, the drug, the protein, or the cells are sensitive to heat, irradiation, or gas treatment, the logic of terminal sterilization cannot simply be adopted and should instead be replaced with an aseptic preparation route.
5.3 Once the sterilization route is determined, pre-sterilization data cannot simply be carried forward
Gelation behavior, rheology, mechanics, swelling, degradation, release, interfacial performance, and key cargo-related properties may all change after treatment. Early data can only describe the pre-sterilization state and cannot replace results obtained under the final route.
5.4 Key concerns under different sterilization or aseptic routes
Sterilization or aseptic route | Situations that may be prioritized | Issues requiring attention | Items that should be rechecked after the route is set |
Terminal heat sterilization | Systems that are relatively heat-stable and whose process allows high-temperature treatment | Viscosity changes, structural alteration, inactivation of heat-sensitive cargo | Gelation time, rheology, mechanics, cargo activity |
Irradiation sterilization | Situations requiring treatment of the finished product, where the material can tolerate irradiation | Chain scission or further crosslinking, performance drift | Molecular structure, mechanics, swelling, degradation |
Low-temperature gas sterilization, such as ethylene oxide | Systems sensitive to temperature and able to tolerate subsequent aeration/desorption procedures | Residual control, aeration/desorption duration, packaging compatibility | Residuals, interfacial performance, shelf life |
Aseptic preparation | Systems unable to tolerate terminal sterilization, or systems containing highly sensitive cargo | A longer process-control chain, with sterility control needing to be moved forward | Raw material sterility, precursor stability, consistency of preparation and forming |
6. Issues that must be clarified before scale-up: whether raw materials, process, and product conditions are stable
When a medical hydrogel moves from bench-scale work toward scale-up, the problems most likely to emerge are often not whether it can form a gel, but whether the raw materials are stable, whether the process is reproducible, and whether performance can still be maintained under actual product conditions. Recent clinical and translational reviews both regard reproducible manufacturing, process scale-up, long-term biocompatibility, and maintenance of performance under real use conditions as important constraints on further progress.
6.1 Raw materials must first be stable
Before scale-up, raw material specifications must be clearly defined. Differences in molecular weight distribution, degree of substitution, impurities, and source of natural polymers can all affect rheology, gelation, and degradation. Although synthetic polymers usually have better consistency, monomer purity, terminal groups, and molecular weight distribution can likewise affect results. If raw material standards are unstable, subsequent process validation becomes difficult to converge.
6.2 Process scale-up can rewrite laboratory results
Conditions that hold at the laboratory stage may not remain unchanged after scale-up. Once manual mixing, local temperature, light intensity, mold size, or forming method changes, the same formulation may yield different results. Injectable systems are more sensitive to mixing uniformity and gelation rate. Photocrosslinked systems are more sensitive to curing depth and energy distribution. Multicomponent systems are more likely to show batch-to-batch variation after scale-up.
6.3 Can the system remain stable under packaging, storage, and transportation conditions?
At the scale-up and translation stage, it is also necessary to examine whether the system remains stable under packaging, storage, and transportation conditions. Whether the precursor solution requires low-temperature storage, whether dehydration or continued swelling is allowed after gelation, whether packaging materials adsorb active molecules, and whether performance drifts during storage can all in turn limit the formulation. If the system also contains drugs, proteins, nucleic acids, or cells, quality control becomes even more difficult, because it is necessary not only to demonstrate the stability of the material itself, but also to show that cargo activity, release consistency, and overall safety can be maintained.
6.4 Summary table of key points that should be confirmed before scale-up
Stage | What should be confirmed before scale-up | Problems that are likely to appear after scale-up |
Raw materials | Molecular weight range, degree of substitution, purity, impurities, source, and batch standards | Differences in rheology, gelation, and degradation appearing under the same formulation |
Process | Mixing method, temperature, light exposure, forming conditions, sequence of operations | Reproducible at small scale, but increased batch variation after scale-up |
Packaging and storage | Packaging materials, storage temperature, shelf life, transportation conditions | Performance drift, loss of activity, interfacial or appearance changes |
Cargo-containing systems | Cargo activity, release consistency, local tolerance, safety | The material remains stable but the cargo becomes inactive, or release becomes inconsistent between batches |
7. Product Navigation Table for Materials and Gelation Strategies Related to Medical Hydrogel R&D (Choose Table 1 to Table 4 Based on Research or Experimental Goals)
Research or experimental goal | Which table to consult first | Why consult this table first | Which table to consult together | Why consult them together |
To first establish a basic hydrogel material framework and distinguish the roles that natural polysaccharides, natural proteins, and synthetic polymers can each play | Table 1, Table 3 | Table 1 brings together natural or naturally derived matrix materials such as hyaluronic acid, alginate, chitosan, gelatin, and cellulose-based materials, while Table 3 focuses on polyethylene glycol, polyvinyl alcohol, polyvinylpyrrolidone, thermoresponsive materials, and polymerizable precursors. Reading the two tables together makes it easier to first clarify the main line of material source. | Table 4 | After the material itself is understood, Table 4 helps translate “which material to choose” into “which gelation, modification, or crosslinking strategy to use.” |
To start from natural polymers for wound dressings, mucosal delivery, or soft tissue repair hydrogels | Table 1 | Sodium hyaluronate, chitosan, alginate, gelatin, sodium carboxymethyl cellulose, and methyl cellulose in Table 1 are all common matrix starting points for this type of research, making it easier to first judge the basis for water retention, film formation, adhesion, ionic gelation, and cell compatibility. | Table 4 | After the natural matrix is selected, it is usually necessary to further examine ionic crosslinking, natural crosslinkers, carboxyl activation, or oxidative activation routes. Table 4 fills in these conditions. |
To develop ionic gelation systems based on alginate or chitosan, or to compare ionic gelation with covalent gelation | Table 1 | Table 1 places ionic-response matrix materials such as alginate and chitosan together first, making it easier to judge the charge properties, swelling behavior, and suitable application directions of the material itself. | Table 4 | Calcium chloride, sodium tripolyphosphate, and subsequent crosslinking routes that can further stabilize the network in Table 4 help place ionic gelation conditions and network stability on the same line for comparison. |
To develop injectable, filling, viscoelastic, or modifiable hydrogels along the hyaluronic acid route | Table 1 | Table 1 includes both hyaluronic acid and sodium hyaluronate, making it suitable for first deciding whether to start from the parent material or the salt form, and whether the focus is more on injectability and flow, water retention and viscoelasticity, or later modification space. | Table 4 | Hyaluronic acid routes often need to be considered together with carboxyl activation, hydrazide linkage, epoxy crosslinking, or vinyl group introduction. Table 4 supplements these later modification routes and residence-time adjustment strategies. |
To develop three-dimensional culture, cell delivery, or tissue repair systems based on collagen, gelatin, fibrinogen, and other materials closer to the extracellular matrix | Table 2 | Table 2 concentrates more biologically active and in situ gelling components such as collagen, fibrinogen, thrombin, and heparin sodium, making it suitable for first judging cell adhesion, tissue integration, and growth factor binding capability. | Table 4, Table 1 | Table 4 can further supplement crosslinking, coupling, and photocuring routes. Gelatin, hyaluronic acid, and similar materials in Table 1 are also often combined with the protein systems in Table 2 to build composite matrices. |
To develop thrombin-fibrinogen systems for rapid gelation, hemostatic sealing, or cell encapsulation | Table 2 | Table 2 places the core gelation components of this route together, making it easier to first establish a basic understanding of “which component is responsible for gelation” and “which component provides the network.” | Table 1 | Once formulation design begins, hyaluronic acid, gelatin, or polysaccharide components are often introduced to adjust viscoelasticity, degradation, and the cellular microenvironment, so Table 1 needs to be revisited. |
To develop thermoresponsive injectable hydrogels, hydrophilic transparent hydrogels, or soft-contact-lens-type hydrophilic networks | Table 3 | Poloxamer, poly(2-hydroxyethyl methacrylate), hydroxyethyl methacrylate, PEG vinyl precursors, and N-vinylpyrrolidone in Table 3 are all common starting points for such studies, making it suitable for first judging thermoresponsiveness, transparency, water content, and network polymerizability. | Table 4 | After the monomer or precursor is selected, crosslinkers, photoinitiators, and vinyl-introducing reagents are still needed. Table 4 completes the gelation conditions. |
To build photocurable, bioprintable, or rapidly in situ curable hydrogel systems | Table 4 | Table 4 brings together photoinitiators, vinyl-introducing reagents, common crosslinkers, and carboxyl-activation reagents, making it suitable for first judging whether the route should proceed via photocuring, chemical coupling, or oxidation-hydrazide chemistry. | Table 1, Table 3 | If the matrix comes from natural materials such as gelatin, hyaluronic acid, or alginate, Table 1 should be consulted together. If the matrix comes from polymerizable precursors such as polyethylene glycol, HEMA, PEGDA, or PEGDMA, Table 3 should be consulted together. |
To compare the differences between “natural matrix routes” and “synthetic polymer routes” in mechanics, degradation, and gelation strategy | Table 1, Table 3 | These two tables represent the main starting points of natural materials and synthetic materials, respectively. Reading them together makes it easier to compare how material source influences later experimental design. | Table 4 | What often truly creates the difference is not only the material itself, but also the crosslinking strategy and network construction route. Table 4 helps clarify this difference. |
To develop composite hydrogels rather than single-material systems, with the aim of balancing cell compatibility, mechanical support, and processability at the same time | Table 1, Table 2, Table 3 | Composite routes usually require simultaneous consideration of natural matrices, bioactive components, and synthetic precursors. Reading the three tables together makes it easier to judge which type of component is responsible for biological function and which type is responsible for network stability and processing performance. | Table 4 | Composite systems ultimately still need to be translated into a specific gelation and crosslinking plan, and Table 4 helps connect the composite materials into a truly stable network. |
If materials are already on hand and the goal is to work backward to determine which crosslinkers, initiators, or activation reagents still need to be added | Table 4 | Table 4 is suitable for checking “what conditions are still missing beyond the matrix itself,” and can quickly identify the key reagents required for ionic crosslinking, natural crosslinking, carboxyl activation, oxidative activation, and photocuring. | Table 1, Table 2, Table 3 | When working backward from conditions, it is still necessary to return to the table where the original material appears, to confirm whether these reagents are compatible with the current matrix and what type of application direction the system will then move toward. |
Note:
In the following product tables, labels such as “injectable grade,” “USP grade,” and “for cell culture use” refer only to catalog specifications or intended-use tags and are not equivalent to raw materials for clinical development. Once the project enters the translational stage, source, sterility/endotoxin, impurities, extractables/leachables, and regulatory suitability still need to be evaluated separately in light of the final product route.
Table 1 | Natural Polysaccharides, Cellulose, and Basic Natural Polymer Matrices
Classification | CAS No. | Aladdin Catalog No. | Name | Specification or Purity | Product Features and Applications |
Sodium hyaluronate matrix | 9067-32-7 | Sodium hyaluronate | Injectable grade, molecular weight: 600,000-1.49 million | Commonly used in high-water-content hydrogels for injection, soft tissue filling, or drug loading, and also suitable as a matrix for cell or growth factor delivery. | |
Natural cationic polysaccharide matrix | 9012-76-4 | Chitosan | Medium viscosity, 200-400 mPa.s | Positively charged and able to form gels with polyanions or crosslinkers; commonly used in wound dressings, mucosal delivery, and antibacterial composite hydrogels. | |
Natural anionic polysaccharide matrix | 9005-38-3 | Alginic acid sodium salt from brown algae | Medium viscosity | Can undergo rapid ionic gelation with calcium ions and is commonly used in cell encapsulation, post-injection in situ gelation, and bioink formulations for bioprinting. | |
Natural protein matrix | 9000-70-8 | Gelatin | Photographic grade, gel strength ~250 g Bloom | Contains cell-adhesive sites and is commonly used as a cell-friendly matrix; it can also be further modified for use in photocurable hydrogels. | |
Cellulose derivative matrix | 9004-32-4 | Carboxymethyl Cellulose Sodium（CMC） | Viscosity: 1000-1400 mPa.s, USP grade | Has good water retention, thickening, and film-forming properties; commonly used in wound dressings, mucosal delivery, and viscosity adjustment in composite hydrogels. | |
Neutral polysaccharide matrix | 9004-54-0 | Dextran | Extra pure | Commonly used as a degradable composite matrix and can also be used in injectable hydrogels and drug delivery systems after oxidation or grafting modification. | |
Cellulose derivative matrix | 9004-67-5 | M657438 | Methyl cellulose（MC） | Animal-free, Low Endotoxin, for cell culture, 1500 mPa.s | Possesses thickening and thermogelling properties and is commonly used in injectable formulations, mucosal delivery, and cell-culture-related hydrogels. |
Cellulose matrix raw material | 9004-34-6 | Cellulose | Microcrystalline powder | Can serve as a starting raw material for cellulose-based gels and derivative modification, and is also commonly used to enhance the structural stability of composite networks. | |
Neutral polysaccharide matrix | 9012-36-6 | Agarose | Ultra high EEO | Forms thermoreversible gels and is commonly used in cell encapsulation, three-dimensional culture, and experimental models related to diffusion and migration. | |
Hyaluronic acid parent material | 9004-61-9 | Hyaluronic acid | Moligand™, from rooster comb | Commonly used to prepare injectable, viscoelastic, or chemically modified hyaluronic acid hydrogels, and is an important parent material for soft tissue and delivery systems. |
Table 2 | Bio-Derived Functional Materials and In Situ Gelling Systems
Classification | CAS No. | Aladdin Catalog No. | Name | Specification or Purity | Product Features and Applications |
Thrombin-fibrinogen gelation component | 9002-04-4 | Thrombin | Biologically active, ActiBioPure™, natural, high performance, EnzymoPure™, from human plasma; 400-1000 NIH U/mg protein | Can rapidly form fibrin gels when combined with fibrinogen, and is commonly used for hemostasis, sealing, and cell delivery. | |
Protein functional additive | 96690-41-4 | Protein hydrolyzates, silk | N≥14.5% | Suitable as a protein-derived functional additive or blending component for adjusting the moisture retention and biological performance of composite hydrogels. | |
Natural structural protein matrix | 9007-34-5 | collagen I from pig | Moligand™, research grade | Commonly used as a three-dimensional matrix that mimics the extracellular matrix and is suitable for studies of cell adhesion, migration, and tissue repair. | |
Bioactive glycosaminoglycan additive | 9041-08-1 | Heparin sodium | Moligand™, anti-Xa potency 110-210 IU/mg | Commonly used to introduce negative charge and bioactive sites, and can also be used to bind growth factors, regulate local release, and improve hemocompatibility. | |
Thrombin-fibrinogen gelation component | 9001-32-5 | Fibrinogen，Bovine Plasma | 50-70% protein (≥85% of protein is clottable) | Forms in situ gelling systems with thrombin and is commonly used in hemostatic adhesion, cell delivery, and tissue repair. |
Table 3 | Synthetic Polymer Matrices, Thermoresponsive Systems, and Polymerizable Network Precursors
Classification | CAS No. | Aladdin Catalog No. | Name | Specification or Purity | Product Features and Applications |
Synthetic hydrophilic polymer matrix | 9002-89-5 | Mowiol® PVA-124(PVA) | Viscosity：54-66 mPa·s | Suitable for freeze-thaw gelation or blending with other networks, and commonly used in dressings, soft tissue support, and drug sustained-release matrices. | |
Synthetic hydrophilic polymer matrix | 25322-68-3 | Poly(ethylene oxide) | Viscosity 65-115 cps | Can be used to improve hydrophilicity, swelling, and chain entanglement, and is also commonly used as a soluble component in spinning or composite hydrogels. | |
Synthetic hydrophilic polymer matrix | 9003-01-4 | Poly(acrylic acid)（PAA） | Viscosity ≤2000 cP (25℃) | Contains carboxyl groups and is suitable for constructing highly absorbent or adhesive hydrogels; also commonly used for stimulus response and drug release regulation. | |
Synthetic hydrophilic polymer matrix | 9003-39-8 | Polyvinylpyrrolidone (PVP) | For plant cell culture, average mol wt 10,000 | Commonly used to regulate hydrophilicity, transparency, and film-forming properties, and can also be blended with other polymers for dressings and mucosal delivery hydrogels. | |
Thermoresponsive gelling matrix | 9003-11-6 | K434429 | Kolliphor® P 407 | Ethylene oxide 71.5-74.9% | A typical thermoresponsive gelling material that flows at low temperature and thickens upon warming, commonly used in injectable or locally retained formulations. |
Hydrophilic monomer | 868-77-9 | 2-Hydroxyethyl methacrylate (HEMA) | Anhydrous, ≥99%, contains 200 ppm MEHQ stabilizer, water ≤0.1% | A classic hydrophilic monomer commonly used to prepare soft contact lenses and transparent hydrophilic hydrogels, and also applicable to drug sustained-release networks. | |
Vinyl-functional network precursor | 26570-48-9 | Poly(ethylene glycol) diacrylate (PEGDA) | Average molecular weight about 200, contains MEHQ stabilizer | A commonly used vinyl-functional polyethylene glycol macromolecular precursor suitable for photocuring or free-radical gelation, often used in systems with tunable mechanics and controlled release. | |
Classic hydrophilic hydrogel matrix | 25249-16-5 | Poly(2-hydroxyethyl methacrylate) | Average Mv 300000, crystalline | A classic medical hydrophilic hydrogel material commonly found in soft contact lenses, and also usable as a transparent drug-loaded or surface-lubricating matrix. | |
Vinyl-functional network precursor | 25852-47-5 | Poly(ethylene glycol) dimethacrylate（PEGDMA） | Average Mn 4000, contains MEHQ as inhibitor | Suitable for constructing relatively stable covalent networks and can be used to regulate gel strength, swelling, and degradation behavior. | |
Reactive microsphere carrier | 106-91-2 | Glycidyl methacrylate(GMA) microspheres | Particle size: 7.0 μm, 2.5% w/v | Contains reactive epoxy sites and can be used to construct functional microspheres or composite hydrogels, and also as particles for surface coupling and drug loading. | |
Hydrophilic comonomer | 88-12-0 | 1-Vinyl-2-pyrrolidone（NVP） | ≥99%, contains 100 ppm NaOH stabilizer | Commonly used as a hydrophilic comonomer to improve hydrogel water content, transparency, and drug diffusion performance. | |
Thermoresponsive monomer | 2210-25-5 | N-Isopropylacrylamide | ≥98%, contains MEHQ stabilizer | A thermoresponsive monomer commonly used to construct stimulus-responsive hydrogels that undergo phase transition near body temperature. |
Table 4 | Crosslinking, Coupling, Oxidation, and Photocuring Reagents
Classification | CAS No. | Aladdin Catalog No. | Name | Specification or Purity | Product Features and Applications |
Aldehyde covalent crosslinker | 111-30-8 | Glutaraldehyde | Photographic grade, 50% in H2O | Used for covalent crosslinking of amino-containing materials such as gelatin, collagen, and chitosan to improve wet-state stability and mechanical strength. | |
Ionic crosslinker | 10043-52-4 | Calcium chloride anhydrous | For insect cell culture, for plant cell culture, ≥96% | A commonly used ionic crosslinker for anionic polysaccharides such as alginate, capable of rapidly adjusting gelation rate and network strength. | |
Small-molecule copolymer crosslinker | 110-26-9 | N,N′-Methylenebis(acrylamide) | For electrophoresis, ≥99%(T) | A commonly used crosslinker in acrylamide and methacrylate systems for improving network density and mechanical stability. | |
Polyanionic crosslinker | 7758-29-4 | Sodium tripolyphosphate | Industrial grade, ≥85% | A commonly used polyanionic crosslinker for chitosan, applicable to the preparation of ionic gels, microspheres, and nanogels. | |
Oxidative activation reagent | 7790-28-5 | Sodium (meta)periodate | UltraBio™, ≥99.5%(RT) | Commonly used for vicinal diol oxidation of polysaccharides; after aldehyde introduction, it can form dynamic or covalent networks with hydrazide- or amino-containing materials. | |
Photoinitiator | 106797-53-9 | I2959 | Moligand™, 10 mM in DMSO | A commonly used photoinitiator with relatively good cell compatibility, suitable for aqueous photocuring and cell-encapsulation hydrogels. | |
Photoinitiator | 85073-19-4 | LAP | Moligand™, 10 mM in DMSO | Has good water solubility and relatively high curing efficiency, and is commonly used in bioprinting and rapidly photocured hydrogels. | |
Vinyl-introducing reagent | 760-93-0 | Methacrylic anhydride | ≥94%, contains 0.2% topanol CA as stabilizer | Commonly used for methacrylation of materials such as gelatin, hyaluronic acid, silk fibroin, and chitosan, introducing photocurable vinyl groups for preparing hydrogel precursors such as GelMA and HAMA. | |
Small-molecule copolymer crosslinker | 97-90-5 | Ethylene glycol dimethacrylate(EGDMA) | Moligand™, 10 mM in DMSO | A commonly used small-molecule dimethacrylate crosslinker for improving network strength and dimensional stability in hydrophilic monomer systems. | |
Natural crosslinker | 6902-77-8 | Genipin | Moligand™, ≥98% | A commonly used natural crosslinker for chitosan, gelatin, and collagen; the crosslinking is relatively mild and is suitable for reducing the swelling and dissolution of materials containing free amino groups. | |
Hydrazide crosslinking/modification reagent | 1071-93-8 | Adipic acid dihydrazide（ADH） | ≥99%(HPLC) | Commonly used with oxidized polysaccharides to form hydrazone-linked networks, and can also be used for chemical modification and crosslinking of materials such as hyaluronic acid. | |
Carboxyl activation reagent | 25952-53-8 | N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride | ≥98% | A commonly used activator for carboxyl-amino coupling, suitable for zero-length crosslinking or grafting of materials such as hyaluronic acid, collagen, and gelatin. | |
Active ester stabilizer | 6066-82-6 | N-Hydroxysuccinimide (NHS) | ≥98% | Commonly used with carbodiimides to form more stable active esters and improve the efficiency of carboxyl-amino coupling. | |
Epoxy crosslinker | 2425-79-8 | 1,4-Butanediol diglycidyl ether（BDDE） | ≥95% | A commonly used epoxy crosslinker for polyhydroxyl materials such as hyaluronic acid, suitable for increasing hydrogel residence time and viscoelastic stability. |
Note: The above are representative Aladdin products. For more product specifications, please search the Aladdin website using “product name/CAS/catalog number.”
References
[1] Clegg JR, Adebowale K, Zhao Z, Mitragotri S. Hydrogels in the clinic: An update. Bioengineering & Translational Medicine. 2024;9(6):e10680. doi:10.1002/btm2.10680.
[2] Lu P, Ruan D, Huang M, et al. Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future directions. Signal Transduction and Targeted Therapy. 2024;9:166. doi:10.1038/s41392-024-01852-x.
[3] Zhang YS, Khademhosseini A. Advances in engineering hydrogels. Science. 2017;356(6337):eaaf3627. doi:10.1126/science.aaf3627.
[4] Correa S, Grosskopf AK, Lopez Hernandez H, et al. Translational Applications of Hydrogels. Chemical Reviews. 2021;121(18):11385-11457. doi:10.1021/acs.chemrev.0c01177.
[5] Bento CSA, Gaspar MC, Coimbra P, de Sousa HC, Braga MEM. A review of conventional and emerging technologies for hydrogels sterilization. International Journal of Pharmaceutics. 2023;634:122671. doi:10.1016/j.ijpharm.2023.122671.
[6] Galante R, Pinto TJA, Colaço R, Serro AP. Sterilization of hydrogels for biomedical applications: A review. Journal of Biomedical Materials Research Part B: Applied Biomaterials. 2018;106(6):2472-2492. doi:10.1002/jbm.b.34048.
[7] Zöller K, To D, Bernkop-Schnürch A. Biomedical applications of functional hydrogels: Innovative developments, relevant clinical trials and advanced products. Biomaterials. 2025;312:122718. doi:10.1016/j.biomaterials.2024.122718.
For more related articles, please see below: